New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2013
07:08 EDTSPPI, LGNDSpectrum gains rights to Capitsol-enabled Melphalan
Spectrum Pharmaceuticals (SPPI) has gained global development and commercialization rights to Ligand Pharmaceuticals’ (LGND) Captisol-enabled, propylene glycol-free (PG-free) melphalan. Captisol-enabled melphalan is currently in a pivotal trial for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. Spectrum is assuming the responsibility for the ongoing pivotal clinical trial and will be responsible for filing an NDA, which is anticipated in the first half of 2014. Under the license agreement, Ligand will receive a license fee and is eligible to receive milestone payments, as well as royalties following potential commercialization.
News For SPPI;LGND From The Last 14 Days
Check below for free stories on SPPI;LGND the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2014
07:13 EDTLGND, SPPILigand's partner Spectrum says Captisol-enabled melphalan meets primary endpoint
Subscribe for More Information
07:10 EDTLGND, SPPISpectrum announces CE Melphalan trial met primary end points
Subscribe for More Information
April 21, 2014
07:05 EDTSPPISpectrum promotes Turgeon to president, COO
Spectrum announced the promotion of Joseph Turgeon to president and COO. Turgeon was previously senior vice president and Chief Commercial Officer. Spectrum also announced the promotion of Thomas Riga to senior vice president, Chief Commercial Officer. Riga was previously vice president, corporate accounts. Ken Keller resigned as executive vice president, COO of the company to pursue other opportunities.
06:49 EDTLGNDLigand May volatility elevated at 81
Subscribe for More Information
April 17, 2014
17:08 EDTSPPISpectrum names Joseph Turgeon COO
Spectrum disclosed in a regulatory filing that effective April 17, Spectrum Pharmaceuticals appointed Joseph Turgeon as its President and COO. Mr. Turgeon will have global responsibility for leading Commercial Operations, Medical and Clinical Development and Pharmaceutical Operations. On April 17, Ken Keller resigned from his position as EVP and COO of the company in order to assume the role of CEO of an organization on the east coast. Mr. Keller will continue to be employed by the company through April 28 in order to assist with the transition. Keller’s resignation was not the result of any disagreement with the company on any matter relating to the company’s operations, policies or practices.
03:59 EDTLGNDLigand volatility at historic high
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use